Strategic Partnerships Massive Bio already collaborates with 60+ pharma and CRO customers and 130+ strategic partners across 17 countries, presenting a scalable path for co-developed trial access solutions and expanded client reach.

AI-Driven Prescreening Their AI-powered patient matching and prescreening capability, recently expanded with partnerships (FOMAT, PrecisCa) and OpenAI recognition, signals strong value in accelerating trial enrollment and reducing dropout, a compelling upsell for sites and sponsors prioritizing efficiency.

Global Scale Operating in North America, Europe, and LATAM with a 200k+ patient onboarded base indicates readiness to support multinational oncology programs and diverse patient populations, appealing to global sponsors and embedded research networks.

Integrated Ecosystem Strategic investments and partnerships (Rivvi, QC Healthcare, Topography Health assets acquisition) point to a expanding AI-enabled engagement infrastructure, enabling bundled solutions for trial recruitment, prescreening, and real-world evidence generation.

Market Positioning Being a founding member of CancerX and participant in the White House Cancer Moonshot, plus recognition as an OpenAI Select Partner, enhances credibility with enterprise customers and can be leveraged to pursue larger, multi-site trial programs and sponsor-led initiatives.